JP2007506726A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007506726A5 JP2007506726A5 JP2006527499A JP2006527499A JP2007506726A5 JP 2007506726 A5 JP2007506726 A5 JP 2007506726A5 JP 2006527499 A JP2006527499 A JP 2006527499A JP 2006527499 A JP2006527499 A JP 2006527499A JP 2007506726 A5 JP2007506726 A5 JP 2007506726A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- pyridyl
- fluorine atoms
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000001153 fluoro group Chemical group F* 0.000 claims 41
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 28
- 125000004076 pyridyl group Chemical group 0.000 claims 28
- 125000000217 alkyl group Chemical group 0.000 claims 23
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 125000001424 substituent group Chemical group 0.000 claims 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 15
- -1 respectively Chemical group 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 11
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 5
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000008238 Muscle Spasticity Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010007710 Cartilage injury Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 206010021118 Hypotonia Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 208000007379 Muscle Hypotonia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008705 Nocturnal Myoclonus Syndrome Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 206010041247 Social fear Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 238000001467 acupuncture Methods 0.000 claims 1
- 230000004075 alteration Effects 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000023515 periodic limb movement disease Diseases 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000005586 smoking cessation Effects 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- 0 CC(C*)CC(CC(O)=O)N Chemical compound CC(C*)CC(CC(O)=O)N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50600303P | 2003-09-25 | 2003-09-25 | |
| PCT/IB2004/002978 WO2005030184A2 (en) | 2003-09-25 | 2004-09-13 | Therapeutic beta aminoacids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007506726A JP2007506726A (ja) | 2007-03-22 |
| JP2007506726A5 true JP2007506726A5 (enExample) | 2007-10-18 |
Family
ID=34393101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006527499A Withdrawn JP2007506726A (ja) | 2003-09-25 | 2004-09-13 | α２δ−タンパク質に対する親和性を有するアミノ酸の使用方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7112610B2 (enExample) |
| EP (1) | EP1670452A2 (enExample) |
| JP (1) | JP2007506726A (enExample) |
| KR (1) | KR100774625B1 (enExample) |
| CN (1) | CN1856301A (enExample) |
| AU (1) | AU2004275572A1 (enExample) |
| BR (1) | BRPI0414798A (enExample) |
| CA (1) | CA2539976A1 (enExample) |
| IL (1) | IL173862A0 (enExample) |
| MX (1) | MXPA06003381A (enExample) |
| NO (1) | NO20061801L (enExample) |
| RU (2) | RU2344121C2 (enExample) |
| TW (1) | TW200511989A (enExample) |
| WO (1) | WO2005030184A2 (enExample) |
| ZA (1) | ZA200602450B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012158795A1 (en) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
| EA025496B1 (ru) | 2011-05-17 | 2016-12-30 | Принсипиа Биофарма Инк. | Ингибиторы тирозинкиназы |
| HUE048834T2 (hu) | 2011-05-17 | 2020-08-28 | Univ California | Kináz inhibitorok |
| US9266895B2 (en) | 2012-09-10 | 2016-02-23 | Principia Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors |
| US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| EP4681737A3 (en) | 2014-02-21 | 2026-03-11 | Principia Biopharma Inc. | Salts and solid form of a btk inhibitor |
| US10485797B2 (en) | 2014-12-18 | 2019-11-26 | Principia Biopharma Inc. | Treatment of pemphigus |
| TW201718572A (zh) | 2015-06-24 | 2017-06-01 | 普林斯匹亞生物製藥公司 | 酪胺酸激酶抑制劑 |
| IL293621B2 (en) | 2016-06-29 | 2023-09-01 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile |
| JP7795454B2 (ja) | 2019-10-14 | 2026-01-07 | プリンシピア バイオファーマ インコーポレイテッド | （ｒ）－２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルを投与することにより免疫性血小板減少症を治療する方法 |
| AU2021209884A1 (en) | 2020-01-22 | 2022-09-15 | Principia Biopharma Inc. | Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2256370T3 (es) * | 1991-08-23 | 2006-07-16 | Nps Pharmaceuticals, Inc. | Moleculas activas para el receptor de calcio. |
| US6306909B1 (en) * | 1997-03-12 | 2001-10-23 | Queen's University At Kingston | Anti-epileptogenic agents |
| FR2791982B1 (fr) * | 1999-04-06 | 2002-12-27 | Inst Nat Sante Rech Med | Inhibiteurs de lta4 hydrolase et leurs applications therapeutiques. |
| WO2002073208A2 (en) * | 2001-03-13 | 2002-09-19 | Queen's University At Kingston | Anti-epileptogenic agents |
| NI200300043A (es) * | 2002-03-28 | 2003-11-05 | Warner Lambert Co | AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA. |
| GB0219024D0 (en) * | 2002-08-15 | 2002-09-25 | Pfizer Ltd | Synergistic combinations |
| CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| US20050043345A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| US20050043407A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| US20050043406A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
-
2004
- 2004-09-13 RU RU2006107650/04A patent/RU2344121C2/ru not_active IP Right Cessation
- 2004-09-13 CN CNA2004800277659A patent/CN1856301A/zh active Pending
- 2004-09-13 AU AU2004275572A patent/AU2004275572A1/en not_active Abandoned
- 2004-09-13 EP EP04769367A patent/EP1670452A2/en not_active Withdrawn
- 2004-09-13 JP JP2006527499A patent/JP2007506726A/ja not_active Withdrawn
- 2004-09-13 WO PCT/IB2004/002978 patent/WO2005030184A2/en not_active Ceased
- 2004-09-13 KR KR1020067005783A patent/KR100774625B1/ko not_active Expired - Fee Related
- 2004-09-13 CA CA002539976A patent/CA2539976A1/en not_active Abandoned
- 2004-09-13 BR BRPI0414798-7A patent/BRPI0414798A/pt not_active IP Right Cessation
- 2004-09-13 MX MXPA06003381A patent/MXPA06003381A/es unknown
- 2004-09-24 TW TW093129003A patent/TW200511989A/zh unknown
- 2004-09-24 US US10/950,094 patent/US7112610B2/en not_active Expired - Fee Related
-
2006
- 2006-02-21 IL IL173862A patent/IL173862A0/en unknown
- 2006-03-24 ZA ZA200602450A patent/ZA200602450B/en unknown
- 2006-04-24 NO NO20061801A patent/NO20061801L/no not_active Application Discontinuation
- 2006-06-30 US US11/480,010 patent/US20060247282A1/en not_active Abandoned
-
2008
- 2008-09-19 RU RU2008137379/04A patent/RU2008137379A/ru not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008137379A (ru) | Терапевтические бета-аминокислоты | |
| CN113365998A (zh) | 用于parp抑制剂的吲哚并七元酰肟类似物 | |
| TW200716648A (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
| RU2006116885A (ru) | Производные n-фенил(пиперидин-2-ил)метил-бензамида, способ получения указанных соединений и их применение в терапии | |
| JP2019505529A5 (enExample) | ||
| JP2011527332A5 (enExample) | ||
| JP2014515351A5 (enExample) | ||
| JP2013508288A5 (enExample) | ||
| TW200738729A (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
| JP2009510044A5 (enExample) | ||
| JP2005511698A5 (enExample) | ||
| WO2009025785A3 (en) | Cb2 receptor ligands for the treatment of pain | |
| JP2015522589A5 (enExample) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2014505107A5 (enExample) | ||
| JP2015522018A5 (enExample) | ||
| JP2013525356A5 (enExample) | ||
| JP2023512664A5 (enExample) | ||
| JP2013063968A5 (enExample) | ||
| JP2020506970A (ja) | ヒドロカルビルスルホニル置換ピリジンおよび癌の治療におけるそれらの使用 | |
| RU2015135824A (ru) | Бициклические соединения пиримидона в качестве ингибиторов lp-pla2 | |
| JP2015502371A5 (enExample) | ||
| JP2014504648A5 (enExample) | ||
| JP2020510061A5 (enExample) | ||
| JP2008526950A5 (enExample) |